Author

Anand A. Patel

Institutions: Huntsman Cancer Institute, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center

Observed institutions: Huntsman Cancer Institute, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center

OpenAlex ID: A5102363736

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model

2026 · Curtis A. Lachowiez, Joshua F. Zeidner, et al. · Journal of Clinical Oncology · 1

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026

2026 · Aaron T. Gerds, Jason Gotlib, et al. · Journal of the National Comprehensive Cancer Network

Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax

2026 · Sabin Filimon, Azin Ghamari, et al. · JACC Advances

Exercises in Clinical Reasoning: Applying High-Value Care When the Counts Don’t Add Up

2026 · Rohan Rao, Katya Lavine, et al. · Journal of General Internal Medicine

Works count: 4

Citation count: 1

H-index: 1

I10-index: